BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20388338)

  • 1. [Safety and immunogenicity of combined hepatitis A and hepatitis B vaccine according to 0 and 6 months schedule in healthy children].
    Wang YL; Chen WY; Xu WG; Wang X; Liu Y; Wu JF; Chen JT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2010 Feb; 44(2):154-6. PubMed ID: 20388338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
    Kurugöl Z; Mutlubaş F; Ozacar T
    Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children].
    Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative study on safety and immunogenicity of an inactivated hepatitis A vaccine in HBsAg carriers and healthy children].
    Chen J; Ren Y; Wu W; Ma S; Li S; Wang J; Kang W; Han L; Gao S; Zhang Y; Liu C
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):380-1. PubMed ID: 12665912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children.
    Roberton D; Marshall H; Nolan TM; Sokal E; Díez-Domingo J; Flodmark CE; Rombo L; Lewald G; Flor Jde L; Casanovas JM; Verdaguer J; Marés J; Esso DV; Dieussaert I; Stoffel M
    Vaccine; 2005 Oct; 23(43):5099-105. PubMed ID: 16055231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Observation on two kinds of recombinant hepatitis B vaccines used in populations with different immunity].
    Zhang H; Ma JX; Gong XH; Liu LR; Wu K; Luo FJ; Zhao W; Zeng ZL; Bai YH; Sun LL; Xu W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Aug; 27(8):690-3. PubMed ID: 17172109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, reactogenicity and adherence to a combined hepatitis A and B vaccine in illicit drug users.
    Lugoboni F; Quaglio G; Pajusco B; Civitelli P; Romanò L; Bossi C; Spilimbergo I; Mezzelani P
    Addiction; 2004 Dec; 99(12):1560-4. PubMed ID: 15585047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.